

## Joint Working Agreement - Executive Summary

<b>1. Project Name:</b>	Pro-active diabetes register management to support diabetes transformation fund to improve the HbA1c treatment target attainment for patients with Type 2 Diabetes Mellitus.
<b>2. Organisations involved with this Joint Working Project are:</b>	Northern, Eastern and Western Devon (NEWD) Clinical Commissioning Group & South Devon and Torbay (SDT) Clinical Commissioning Group Eli Lilly and Company
<b>3. The objectives for this project are:</b>	<p>Devon STP are aiming to improve HbA1c attainment rates in diabetic patients with an HbA1c over 58 mmol/mol (7.5%).</p> <p>This project will utilise NHS data, develop algorithms and cohort charts to aid in the identification and treatment of patients not currently meeting HbA1c treatment targets. A community DSN or relevant clinician/commissioner will run workshops for local GP practices in which they will identify patients using pseudonymised patient data who may require a clinical intervention using this data, along with the tools developed.</p> <p>Main objectives are:</p> <ul style="list-style-type: none"> <li>• Improvement in glycaemic control of patients with type 2 diabetes.</li> <li>• Improvement in the number of patients achieving an HbA1c of less than 58 mmol/mol (7.5%)</li> <li>• Implementation of innovative primary care analytics</li> <li>• Medicines optimisation</li> <li>• Improve GP and Practice Nurse confidence in managing diabetes conditions</li> <li>• Increase pro-active management and case finding for diabetes at the practice</li> </ul> <p>It is also planned that the project outcomes will be shared via publication in a suitable clinical journal or trade press.</p> <p>The intention is that the project encourages sustainable change so the work over the course of the project may continue when the project is completed.</p>
<b>4. Roles and Responsibilities, including any funding</b>	The role of Lilly UK within the project is to provide a Key Account Manager (KAM) to sit on the working group; 0.2 FTE KAM/Project Manager (1 day/week.) The role of Lilly, and the Lilly KAM will be to facilitate workshops throughout the project to allow the diabetes team to develop a tool to recall, review and manage the patients; which will be used in conjunction with local formularies and guidance. This information will also be used to support capacity planning, and allow the DSN (diabetes specialist nurse) to allocate resources.

## Joint Working Agreement - Executive Summary

	<p>No patient identifiable data will be used or discussed across any elements of the project.</p> <p>Lilly KAM</p> <ul style="list-style-type: none"> <li>• Project management using Prince 2 methodology including             <ul style="list-style-type: none"> <li>○ Project support and version control of documents associated with PARM (Pro-Active Register Management) Diabetes Tool and virtual clinics</li> <li>○ Support the CCG's to evaluate progress achievement of the 3TTs (3 treatment targets).</li> </ul> </li> <li>• Supporting the role out of the Pro Active Register Management (PARM) Diabetes Tool to the wider diabetes team at meetings as part of the project working group.</li> </ul>
<b>5. The expected benefits for patients on delivery of this project are:</b>	<ul style="list-style-type: none"> <li>• Medicines optimisation to improve blood glucose control leading to a delay in the onset of complications which can impact patient quality of life</li> <li>• Improved lipid and renal control associated with holistic diabetes review using specialist support</li> <li>• Care delivered closer to home through an increased management of diabetes by GPs and practice nurses</li> <li>• Increase in patient satisfaction with the community diabetes service</li> </ul>
<b>6. The expected benefits for the partner organisation(s) on delivery of this project are:</b>	<ul style="list-style-type: none"> <li>• Improved attainment of CCG IAF (both CCGs are currently inadequate).</li> <li>• Reduction in inappropriate use of secondary care services and associated costs.</li> <li>• Improved patient engagement.</li> <li>• Improved efficiency within the service freeing up capacity.</li> <li>• Improved confidence of GPs and practice nurses managing patients with diabetes.</li> <li>• Highlighting areas of best practice to share with colleagues locally and nationally.</li> <li>• Leave a framework legacy to help achieve the National Diabetes Audit (NDA) 3 treatment targets.</li> </ul>
<b>7. The expected benefits for Lilly UK on delivery of this are:</b>	<ul style="list-style-type: none"> <li>• Appropriate use of diabetes medications (which includes Lilly diabetes medicines) strictly adhering to local formulary guidelines currently in place – right patient, right place, right time</li> <li>• Opportunity to understand patient flow throughout the type 2 patient pathway across Devon STP.</li> <li>• Opportunity to demonstrate partnership working with the NHS</li> <li>• Publication of the project outcomes would demonstrate Lilly's integrity and commitment to the NICE and NHS England guidance of putting the patient at the centre of treatment decisions, and alignment to current national diabetes strategy.</li> </ul>